



Date: 26th April, 2023

То	То
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza
Dalal Street	Bandra Kurla Complex, Bandra (E)
Mumbai- 400001	Mumbai-400051
Security Code: 540596	Security Code: ERIS

Dear Sir/Madam,

Ref.: Chapter XII of the SEBI Operational Circular No- SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as updated on 13 April 2022, for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper, as amended ("Circular")

Sub: Submission of Initial Disclosure to be made by an entity identified as a Large Corporate

Pursuant to the provisions mentioned in paragraph 1.2 of Chapter XII of the aforementioned Circular, the Company hereby confirms that it does not qualify as a Large Corporate as on March 31, 2023.

As per stock exchange circulars, listed entities which do not identify as large corporates must submit a confirmation in this regard to exchanges.

Disclosure confirming the same is enclosed herewith as "Annexure-1".

We request you to kindly take the same on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar Company Secretary & Compliance Officer

Encl: As above





"Annexure-1"

Format of the initial disclosure to be made by an Identified as Large corporate:

Sr. No.	Particulars	Details
1.	Name of the Company	Eris Lifesciences Limited
2.	Corporate Identification Number (CIN)	L24232GJ2007PLC049867
3.	Outstanding borrowing of Company as on 31 st March 2023, as applicable*	Rs. 262.50 Crores
4.	Highest credit rating during the previous FY along with name of the CRA [#]	NA
5.	Name of stock exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	NA

*Data pertains to Long Term Outstanding Borrowing of the Company

[#]No credit rating from any Credit Rating Agency has been obtained by the Company on or before 31 March 2023.

We, Eris Lifesciences Limited, confirm that we are <u>not a Large Corporate</u> as per the applicability criteria mentioned in paragraph 1.2 of Chapter XII of the SEBI Operational circular dated August 10, 2021 (updated as on April 13, 2022).

For Eris Lifesciences Limited

For Eris Lifesciences Limited

Milind Talegaonkar Company Secretary and Compliance Officer Membership No.: A26493 Email: complianceofficer@erislifesciences.com Sachin Shah Chief Financial Officer

Email: sachin@erislifesciences.com